CGEM Cullinan Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1789972 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY6.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-55.5%
ROA-50.4%
ROIC (approx.)-63.9%
Asset turnover—
Leverage & solvency
Liabilities / assets12.8%
Debt / equity0.00x
Current ratio7.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $40.17M | $44.44M | $42.12M | $42.95M | $41.97M | $61.03M | $41.46M | $40.49M |
| SG&A expense | $12.43M | $12.82M | $11.57M | $12.31M | $13.63M | $14.77M | $13.54M | $14.56M |
| Operating income | -$52.60M | -$57.25M | -$53.70M | -$55.26M | -$55.59M | -$75.80M | -$55.00M | -$55.05M |
| Net income | -$49.39M | -$53.70M | -$49.66M | -$50.71M | -$50.61M | -$70.06M | -$48.50M | -$47.65M |
| EBITDA | -$52.55M | -$57.17M | -$53.62M | -$55.18M | -$55.52M | -$75.72M | -$54.92M | -$54.97M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $88.26M | $78.64M | $75.08M | $88.33M | $103.33M | $72.82M | $76.66M | $83.00M |
| Short-term investments | $201.31M | $255.90M | $276.80M | $289.56M | $229.26M | $192.66M | $227.17M | $315.97M |
| Current assets | $298.15M | $341.97M | $361.41M | $386.76M | $342.24M | $275.91M | $317.77M | $414.67M |
| PP&E, net | $210,000 | $263,000 | $342,000 | $421,000 | $489,000 | $569,000 | $607,000 | $683,000 |
| Total assets | $322.56M | $363.79M | $402.98M | $448.37M | $484.13M | $520.33M | $579.68M | $621.82M |
| Current liabilities | $40.13M | $40.63M | $35.15M | $37.74M | $32.76M | $28.06M | $27.35M | $30.65M |
| Total liabilities | $41.27M | $42.03M | $36.81M | $39.64M | $32.76M | $28.18M | $27.84M | $31.50M |
| Shareholders' equity | $281.28M | $321.75M | $366.17M | $408.73M | $451.37M | $492.15M | $551.84M | $590.33M |
| Shares outstanding | 64.90M | 64.35M | 61.45M | 60.24M | 59.08M | 59.07M | 58.70M | 58.51M |
| Cash flow statement | ||||||||
| Operating cash flow | -$43.08M | -$38.22M | -$46.05M | -$38.11M | -$36.88M | -$57.61M | -$43.16M | -$36.63M |
| Capital expenditure | — | — | — | $11,000 | — | — | — | $0 |
| Free cash flow | — | — | — | -$38.12M | — | — | — | -$36.63M |
| Investing cash flow | $51.64M | $40.68M | $32.41M | $22.39M | $67.39M | $53.40M | $36.80M | $15.96M |
| Financing cash flow | $1.06M | $1.10M | $380,000 | $715,000 | $0 | $373,000 | $0 | $1.58M |
| Depreciation & amortization | $53,000 | $79,000 | $79,000 | $79,000 | $79,000 | $77,000 | $76,000 | $77,000 |
| Stock-based compensation | $8.37M | $8.45M | $7.62M | $7.31M | $9.47M | $9.89M | $9.37M | $9.63M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.